Skip to content

Outcome of Cardiomyopathic Adults Admission in ICU.

Characteristics and Outcomes of Heart Failure-Related Intensive Care Unit Admissions in Adults With Cardiomyopathy.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05567445
Enrollment
45
Registered
2022-10-05
Start date
2023-09-30
Completion date
2024-10-31
Last updated
2022-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies

Brief summary

To study the outcome of the cardiac function, and clinical status of the patiants with cardiomyopathy who are admitted in the I.C.U.

Detailed description

Heart failure is not a single pathological diagnosis, but a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles, and peripheral oedema). It is due to a structural and/or functional abnormality of the heart that results in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise. Identification of the aetiology of the underlying cardiac dysfunction is mandatory in the diagnosis of HF as the specific pathology can determine subsequent treatment. Most commonly, HF is due to myocardial dysfunction: either systolic, diastolic, or both. However, pathology of the valves, pericardium, and endocardium, and abnormalities of heart rhythm and conduction can also cause or contribute to HF. Cardiomyopathies are defined by the WHO as diseases of the myocardium associated with cardiac dysfunction, Cardiomyopathies are categorized into dilated, restrictive, hypertrophic, and unclassified based on the predominant pathophysiologic characteristics. A new category has been added to include right ventricular abnormalities. The disorders that are associated with systemic or certain cardiac diseases are called specific heart muscle diseases and include ischemic cardiomyopathy, valvular, hypertensive, inflammatory, metabolic, peripartal, general systemic disease, muscular dystrophies, neuromuscular disorders, and toxic and hypersensitivity reactions. The unclassified cardiomyopathy category includes disorders such as fibroelastosis, noncompacted myocardium, and systolic dysfunction with minimal dilation. Patiant admitted in I.C.U. with heart failure who already have cardiomyopathy Some patiants discharge without any comorbidies and some acquire renal failure, respiratory failure,MCS, sepsis, and some were associated with mortality . Significant comorbidities associated with these hospitalizations included arrhythmias, renal failure , cerebrovascular disease, and hepatic impairment.

Interventions

DIAGNOSTIC_TESTEchocardiography, CBC, Liver function, kideny function

Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Cardiomyopathic patiants admitted with heart failure diagonsed clinicaly , by Echocardiograph , or by ECG. 1. Dilated cardiomyopathy\[ Unknown, Uremic cardiomyopathy, Post-partum, Ishemic\]. 2. Hypertrophic cardiomyopathy. 3. Acute heart failure caused by A.C.S. , Toxic myocardititis.

Exclusion criteria

1. Heart failure due to valvular heart disease. 2. Heart failure caused by hypertension. 3. patiant with COPD

Design outcomes

Primary

MeasureTime frameDescription
Effect on E.F.through study completion, an average of 1 yearDegree of impairement of E.F.
Effect on renal functionthrough study completion, an average of 1 yearWho developed renal impairement, and its effect on cardiac function.
Sepsisthrough study completion, an average of 1 yearWho developed sepsis and its effect on cardiac function.
Effect on liver functionthrough study completion, an average of 1 yearWho suffer liver function impairement, improvement or deteroriation

Contacts

Primary ContactMohammed Ahmed Abdelhmied, Doctor
Abdelhmied22@gmail.com01147349160

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026